Gastroesophageal Junction Adenocarcinoma – VJRegenMed
https://mirror.vjregenmed.com
The Video Journal of Regenerative MedicineTue, 12 Oct 2021 15:16:37 +0000en-US
hourly
1 https://wordpress.org/?v=6.5.2https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.pngGastroesophageal Junction Adenocarcinoma – VJRegenMed
https://mirror.vjregenmed.com
3232Adaptimmune: SPEAR T-cells
https://mirror.vjregenmed.com/video/w_-zxokavpg-adaptimmune-spear-t-cells/
Tue, 03 Nov 2020 17:39:49 +0000http://13.40.107.223/video/w_-zxokavpg-adaptimmune-spear-t-cells/TCR T-cell therapies (SPEAR T-cells) hold the potential to treat a wide range of cancers. In this video, Helen Tayton-Martin, Chief Business Officer, Adaptimmune, Oxford, UK. discusses the SPEAR T-cells currently under development with Adaptimmune. Dr Taytor-Martin goes on to discuss Adaptimmune’s partnership with GlaxoSmithKline (GSK) and recent advances such as the SURPASS trial (NCT04044859) which investigated ADP-A2M4CD8 in HLA-A2+ subjects with MAGE-A4 positive tumors. This interview took place during the 2020 Meeting on the Mesa congress.
]]>